ID   PC-9/GR1
SY   PC-9 GR1
DR   cancercelllines; CVCL_DI28
DR   GEO; GSM481161
DR   Progenetix; CVCL_DI28
DR   Wikidata; Q54938494
RX   PubMed=20118985;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Iressa).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 13
RX   PubMed=20118985; DOI=10.1038/onc.2009.526;
RA   Ercan D., Zejnullahu K., Yonesaka K., Xiao Y., Capelletti M.,
RA   Rogers A., Lifshits E., Brown A., Lee C., Christensen J.G.,
RA   Kwiatkowski D.J., Engelman J.A., Janne P.A.;
RT   "Amplification of EGFR T790M causes resistance to an irreversible EGFR
RT   inhibitor.";
RL   Oncogene 29:2346-2356(2010).